Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation

The treatment of bone metastases is a thorny issue. Immunotherapy may be one of the few hopes for patients with unresectable bone metastases. Immune checkpoint inhibitors are the most commonly used immunotherapy drugs currently. In this review, the characteristics and interaction of bone metastases...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chang Liu, Miao Wang, Changli Xu, Bo Li, Juxiang Chen, Jianchun Chen, Zhiwei Wang
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2021/8970173
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Tumor microenvironment immunotherapy: Transforming cancer treatment and immune checkpoint inhibitors - Future directions and challenges
by: Jeeva Jothi Kumaravel, et al.
Published: (2024-06-01)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01)

Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
by: Yunyan Dai, et al.
Published: (2025-01-01)

Gut Microbiota–Tumor Microenvironment Interactions: Mechanisms and Clinical Implications for Immune Checkpoint Inhibitor Efficacy in Cancer
by: Said SS, et al.
Published: (2025-01-01)

Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
by: Xuhui Tong, et al.
Published: (2025-01-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)

Immune infiltrate populations within distinct tumor immune microenvironments predictive of immune checkpoint treatment outcome
by: Brian Z Ring, et al.
Published: (2025-01-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
by: Coraline Radermecker, et al.
Published: (2021-03-01)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01)

Multiple stellate keratitis during immune checkpoint inhibitor therapy
by: Isana Nakajima, et al.
Published: (2025-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
by: Sandra M Herrmann, et al.
Published: (2023-01-01)

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
by: Douglas B Johnson, et al.
Published: (2024-07-01)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
by: Maansi Joshi, et al.
Published: (2020-01-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Immunotherapeutic Potential of Lactobacillus Species as Immune Checkpoint Inhibitors in Cancer Immunotherapy
by: Renukadevi J, et al.
Published: (2025-01-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Current Situation about Dispute of Bone Convergence
by: Zhuile WU, et al.
Published: (2016-08-01)

Interaction among Cells of Bone, Immune System, and Solid Tumors Leads to Bone Metastases
by: Ilaria Roato
Published: (2013-01-01)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations
by: Andrew H. Coles
Published: (2025-03-01)

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy
by: Kun Wang, et al.
Published: (2025-01-01)

Immunotherapy revolutionizing buccal carcinoma treatment: Harnessing immune checkpoint inhibitors to overcome immune evasion mechanisms
by: S. Menaka
Published: (2024-06-01)

The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC
by: Yifan Wang, et al.
Published: (2025-01-01)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
by: Ryan S. Chiang, et al.
Published: (2020-01-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival
by: Yin Leung, et al.
Published: (2025-01-01)

Krebs von den Lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis
by: Isamu Okamoto, et al.
Published: (2024-12-01)

Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)
by: Iadalin Ryntathiang, et al.
Published: (2024-09-01)